#USA #San Diego #Cancer Treatment #Aethlon Medical #Hemopurifier

Aethlon Medical Reports Fourth Quarter Results and Advances in Cancer Research

Aethlon Medical, Inc. has recently announced its financial performance for the fourth quarter ending March 31, 2025, and provided updates on several significant developments concerning its product pipeline. The company, which specializes in therapeutic medical devices mainly aimed at combating cancer and serious infectious diseases, showcased noteworthy achievements in its ongoing trials and operational adjustments.

Key Highlights in Fiscal Year 2025

In the last quarter, Aethlon made progress in various fronts:

• - Trial Advancements: The company treated its first three patients with the Hemopurifier® in a study focusing on solid tumors that do not respond to conventional therapies, specifically anti-PD-1 agents. Treatments took place at esteemed Australian medical institutions, including Royal Adelaide Hospital and Royal North Shore Hospital.
• - Regulatory Approval in India: Aethlon received the green light from India's Central Drugs Standard Control Organization (CDSCO) for a similar oncological study, expanding its research avenues and patient recruitment in regions beyond the United States.
• - Operational Efficiency: Through strategic operational changes, Aethlon reduced its expenses significantly this fiscal year, enabling a more focused approach to clinical and regulatory objectives.

Clinical Trial Progress

The company's clinical trials have displayed a promising trajectory. In January 2025, the first patient underwent the Hemopurifier® treatment, followed by two more enrollees completing their treatments in June. Each patient underwent a four-hour procedure without complications, concluding a seven-day safety evaluation successfully. The data from this initial cohort, including the treatment's impact on extracellular vesicles (EVs) and T-cell activity, is anticipated in the coming months.

The protocol for the trial was updated to allow the inclusion of patients who are on combination therapies with leading immunotherapies, Pembrolizumab (Keytruda®) and Nivolumab (Opdivo®). The Hemopurifier® aims to remove tumor-derived EVs from the bloodstream, which are linked to cancer progression and therapeutic resistance, thereby enhancing patient responses to treatments like anti-PD-1 therapies.

Groundbreaking Research and Findings

In May 2025, results from a preclinical ex vivo study underscored the Hemopurifier’s efficacy, showing it could eliminate up to 98.5% of platelet-derived extracellular vesicles from human plasma. This breakthrough not only supports ongoing oncological initiatives in Australia but also suggests potential applications for this technology in numerous diseases, including various autoimmune disorders and conditions like Long COVID, which affects millions.

Moreover, Aethlon’s collaboration with the UCSF Long COVID Clinic is generating exciting research aimed at understanding the unique implications of EVs in post-viral syndromes. This collaborative effort will be showcased at the upcoming Keystone Symposium in August 2025.

Financial Performance Update

As of March 31, 2025, Aethlon reported a cash balance of approximately $5.5 million. The company's consolidated operating expenses saw a reduction to $9.3 million for the fiscal year compared to $12.6 million the previous year, driven by lower payroll, administrative costs, and professional fees. This operational streamlining is expected to stabilize the company's financial standing as it pushes forward with its research and development goals.

Despite challenges, including a non-cash charge from a warrant inducement offer, the overall operational loss has decreased, laying the groundwork for future financial health and continued innovation in therapeutic treatments.

Moving Forward

Aethlon Medical’s ongoing endeavors in cancer research, particularly with the Hemopurifier®, represent a significant step toward addressing unmet medical needs both in the oncology space and potentially in managing persistent symptoms associated with Long COVID. The company's approach to refining its operational model while expanding its clinical studies illustrates a commitment to innovation and responsiveness to emerging health challenges. As Aethlon prepares for future developments, including the anticipated outcomes of its ongoing trials and presentations, stakeholders remain optimistic about its role in advancing medical therapeutics.

For those interested in further discussions or insights regarding Aethlon’s efforts, a conference call will take place today at 4:30 p.m. ET, where management will delve into the financial results and field inquiries from the public. Those who wish to participate can register online or dial in using the provided contact numbers.

For more on Aethlon Medical, visit their official site at www.AethlonMedical.com.